This is just the beginning, many catalysts yet to come this year...

This is just the beginning, many catalysts yet to come this year which will support the share price.


- CPT Reimbursement code for PromarkerD
- Giardia validation of prototype immunoassay
- Endometriosis clinical study (partnership)
- Asthma & COPD discovery results, if positive will move into POC stage
- Plant Dieback discovery results, if positive will move into POC stage
- Diabetic Retinopathy discovery results, if positive will move into POC stage
- Oxidative Stress (2-tag) - Clinical validations pending & commercial discussions.
- Licensing partnership for mass spectrometry cancer biomarker test
- Further distribution/license deals for PromarkerD

+COVID19 studies.

Let's not forget our new Ace card too - Promarker it self could become a standard mass spectrometry diagnostics platform -

From recent ASX Ann:
PromarkerD assay performance studies also illustrate the potential for adoption of Proteomics International's PromarkerTM mass spectrometry diagnostics platform in future clinical practice. The Company has positioned its R&D arm at the forefront of this technological approach, which has the potential to overtake current immunoassay technology and assume mainstream use in clinical pathology laboratories.

I will be very disappointed if we don't close $1 by Friday.